Skip to main content

$0.210 (0.00%)

High

$0.22

Low

$0.18

Trades

93

Turnover

$118,368

Volume

595,975
30 June 2023 at 3:57pm
Register to track EOF and receive email alerts.

Ethics Approval for Phase IIb clinical trial in Australia

StockBot

416,823 posts

EOF released this announcement to the ASX on 19 April 2021, 10:29. The announcement is not marked as price sensitive, and is 6 page(s) in length and 3.17MB in size.

You can view all announcements from EOF and see how they appear on a price chart on the announcements page.

At the date of this announcement, EOF was 0.834% short sold according to ASIC data. It was ranked the 206th most shorted stock on the ASX. It remains ranked 540th as of the latest reported data (27 November 2024).

Other Recent Announcements from EOF
Change in substantial holding 30 June 2023, 10:31
Letter to Shareholders 11 May 2023, 8:20
Quarterly Activities/Appendix 4C Cash Flow Report 28 April 2023, 8:15
Ethics Approval for Phase IIb clinical trial in Australia 19 April 2021, 10:29
Appendix 2A 1 April 2021, 10:59
Notification of Release of Escrowed Shares 19 March 2021, 11:03
Initial Director's Interest Notice 9 March 2021, 13:15
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track EOF and receive email alerts.